3rd Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,470,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 4574/ HR 8254-Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act. Final Rule for Medicare Advantage program requirements for contract years 2021 and 2022. COVID-19 emergency aid packages. Telehealth policies/CMS Waivers. CY 2021 Proposed Rule on the End-Stage Renal Disease Prospective Payment System (ESRD PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. The Administrations CMMI Model for Kidney Disease - ESRD Treatment Choices Model & KCC Model. S. 3548-Coronavirus Aid, Relief, and Economic Security (CARES) Act & future COVID-19 relief packages. Centers for Medicare & Medicaid Services (CMS) final Medicare Advantage (MA) and Part D rule. ESRD Seamless Care Organizations (ESCO) Models. Milcon-VA Appropriations. ESRD Prospective Payment System.

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 8254 (116th), S. 4574 (116th), S. 3548 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.